US20100015285A1 - Process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature - Google Patents
Process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature Download PDFInfo
- Publication number
- US20100015285A1 US20100015285A1 US12/564,744 US56474409A US2010015285A1 US 20100015285 A1 US20100015285 A1 US 20100015285A1 US 56474409 A US56474409 A US 56474409A US 2010015285 A1 US2010015285 A1 US 2010015285A1
- Authority
- US
- United States
- Prior art keywords
- milk beverage
- process according
- cell count
- viable cell
- ambient temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000020124 milk-based beverage Nutrition 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 41
- 230000008569 process Effects 0.000 title claims abstract description 40
- 235000013361 beverage Nutrition 0.000 claims abstract description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 claims abstract description 14
- 235000020167 acidified milk Nutrition 0.000 claims abstract description 14
- 230000001737 promoting effect Effects 0.000 claims abstract description 10
- 239000004310 lactic acid Substances 0.000 claims abstract description 8
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 8
- 230000001954 sterilising effect Effects 0.000 claims abstract description 5
- 235000013336 milk Nutrition 0.000 claims description 11
- 239000008267 milk Substances 0.000 claims description 11
- 210000004080 milk Anatomy 0.000 claims description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 229930091371 Fructose Natural products 0.000 claims description 5
- 239000005715 Fructose Substances 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 235000020122 reconstituted milk Nutrition 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 2
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- -1 aescine Chemical compound 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims description 2
- 229940089837 amygdalin Drugs 0.000 claims description 2
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000271 arbutin Drugs 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 2
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 229950006191 gluconic acid Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims description 2
- 229940120668 salicin Drugs 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 7
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 235000015140 cultured milk Nutrition 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 15
- 241000186660 Lactobacillus Species 0.000 description 11
- 229940039696 lactobacillus Drugs 0.000 description 11
- 235000008939 whole milk Nutrition 0.000 description 9
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 3
- 235000010358 acesulfame potassium Nutrition 0.000 description 3
- 239000000619 acesulfame-K Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the invention relates to milk beverage field, in particular, a process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature.
- Direct-acidified milk beverage is highly appreciated by consumers especially children and women because of its smooth, sweet and sour taste.
- acidulants, sweeters, flavourings, thickening and emulsifying stabilizers are added and mixed together to obtain acidified milk beverage containing more than 1.0% protein, and after being sterilized, its shelf life can reach to 3-6 months. Since such products are not fermented by lactic acid bacteria, the nutrition value is not high.
- lactobacillus it is desirable for the manufactory of acidified milk beverage that viable lactobacillus can be added into direct-acidified milk beverage and kept viable for long time without negative influence to its taste.
- lactobacillus it will metabolize lactose to produce lactic acid, thereby make the mouthfeel of product unacceptable to consumers.
- the activity of lactobacillus is decreased gradually; by the end viable cell count can not be measured. And ambient temperature environment will speed up the process greatly.
- Lactobacillus rhamnosus (available from American Type Culture Collection, bacterial strain number: ATCC 53103 ) is a probiotic strain isolated from healthy human body (U.S. Pat. No. 4,839,281; U.S. Pat. No. 5,032,399), and it can get rid of endotoxin from blood plasma (U.S. Pat. No. 5,413,785).
- the distinctive character of this bacterium is that it does not metabolize lactose and is resistant to acid and oxygen. Since this bacterium has the function of prevention and treatment of stomach upset (such as diarrhea) and improvement of immunity, it is used in healthy and functional products (such as yoghourt).
- One aspect of the invention is to provide a process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature.
- the process according to an embodiment of the invention includes: according to the characters of Lactobacillus rhamnosus ATCC 53103 that it can not metabolize lactose to produce lactic acid and can survive for a long time, adding this bacterium into direct-acidified milk beverage under aseptic conditions, meanwhile adding 0.01-5% wt of growth promoting factors, thereby obtaining direct-acidified milk beverage keeping high viable cell count at ambient temperature during storage.
- ambient temperature refers to a temperature which can be reached indoor under normal conditions, such as 0-40° C., preferably 10-30° C.
- milk is directly acidified to pH value 4.0-4.5 without fermentation, so as to obtain acidified milk beverage. Then sterilize and add concentrated culture, concentrated frozen culture or freeze dried culture of Lactobacillus rhamnosus ATCC 53103 together with 0.01-3% wt of growth promoting factors under aseptic condition.
- said milk beverage is made from fresh milk or reconstituted milk (including but not limited to fresh milk or reconstituted milk of cow milk or goat milk).
- the protein concentration of the milk beverage is 0.1-4%.
- the protein concentration of the milk beverage is 0.7-2.5%.
- the acidulants for adjusting pH value can be any acidulants which are known by people skilled in the art, such as one or more of citric acid, lactic acid and malic acid.
- the pH value of finished product of direct-acidified milk beverage is 3.5-4.8, preferably 3.7-4.4.
- the addition amount of Lactobacillus rhamnosus ATCC 53103 is not limited theoretically. According to the principle of economy and effectiveness, the addition amount of Lactobacillus rhamnosus ATCC 53103 is 10 3 -10 8 cfu/ml milk beverage, preferably 10 4 -10 7 cfu/ml milk beverage.
- growth promoting factors can be any growth promoting ingredients known by people skilled in the art that can be utilized by Lactobacillus rhamnosus except lactose.
- said growth promoting factors can be selected from one or more of glucose, fructose, galactose, arabinose, ribose, mannose, rhamnose, fucose, tagatose, sucrose, maltose, cellobiose, trehalose, melizitose, gentiobiose, galactitol, mannitol, sorbitol, inositol, gluconic acid, salicin, aescine, arbutin, amygdalin and acetylglucosamine, and the addition amount is 0.01-5% wt. It can be added together with milk base before sterilization or with Lactobacillus rhamnosus ATCC 53103 after sterilization under as
- the growth promoting factors are selected from one or more of glucose, fructose, galactose and sucrose, the addition amount is 0.05-3% wt.
- Sweeters, flavorings, stabilizers and preservatives can also be added into the above-mentioned direct-acidfied milk beverage.
- sweeters can be selected from one or more of aspartame, Acesulfame-K (Ace-K), Sodium cyclamate, stevia sugar (stevioside) and Trichlorosucrose. And the addition amount can be 0.001-5 g/L, preferably 0.1-1 g/L.
- Flavourings can be selected as seasoners, and the addition amount can be 0.001-5 g/L, preferably 0.1-1 g/L.
- Stabilizers are selected from one or more of pectin, gelatin, modified starch, glyceryl monostearate, sucrose esters and sodium carboxymethyl Cellulose, and the addition amount can be 0.001-12 g/L, preferably 0.1-10 g/L.
- Preservatives are selected from one or more of natamycin and potassium sorbate. And the addition amount is 0.001-3 g/L, preferably 0.005-0.5 g/L.
- the direct-acidified milk beverage prepared by the process according to an embodiment of the invention can be stored for 1-6 months under room temperature (10-30° C.) and keep viable cell count at least 105 cfu/ml milk beverage.
- the indexes of storage period and viable cell count are much higher than fermented milk beverage prepared by conventional process. Thereby the defects that directed-acidified milk beverage has no viable Lactobacillus and has low nutritional value are overcome.
- Example 2 With the same process in Example 1, make reconstituted whole milk with 4.5% whole milk powder, and acidify it. Adjust the pH value of the mixture to 4.0 with 10% lactic acid. Homogenize and sterilize, then cool it down to below 37° C., add Lactobacillus rhamnosus ATCC 53103 (freeze dried culture powder) with quantity of 2 ⁇ 10 6 cfu/ml and 0.15% galactose into above-mentioned milk beverage aseptically, store it at 12-25° C. Measure its acidity and viable cell count during storage. The results are listed in table 3
- Example 2 With the same process in Example 1, make reconstituted whole milk with 7% whole milk powder, and acidify it. Adjust the pH value of the mixture to 4.4 with 10% malic acid. Homogenize and sterilize, then cool it down to below 37° C., add Lactobacillus rhamnosus ATCC 53103 ( concentrated frozen culture) with quantity of 2 ⁇ 10 7 cfu/ml and 0.02% fructose into above-mentioned milk beverage aseptically, store it at 12-25° C. Measure the pH value and viable cell count during storage. The results are listed in table 4.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Dairy Products (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
The invention provides a process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature. The process means that, adopting conventional technology to prepare acidified milk beverage and sterilizing, then adding Lactobacillus rhamnosus ATCC 53103 and certain quantity of growth promoting factors under aseptic condition. According to various pH value, the product can be stored at ambient temperature for 1-6 months and the viable cell count will not be less than 105 cfu/ml milk beverage. The indexes of storage period and viable cell count are much higher than fermented milk beverage prepared by conventional process. Thereby it overcomes the defects that direct-acidified milk beverage with long shelf life has no viable lactic acid bacteria and has low nutritional value.
Description
- This application is a continuation-in-part of international application No. PCT/CN2007/002035 filed on Jun. 29, 2007, which claims the priority benefits of China application No. 200710064896.X filed on Mar. 28, 2007. The contents of these prior applications are hereby incorporated by reference in its entirety.
- The invention relates to milk beverage field, in particular, a process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature.
- Direct-acidified milk beverage is highly appreciated by consumers especially children and women because of its smooth, sweet and sour taste. Using milk as base, acidulants, sweeters, flavourings, thickening and emulsifying stabilizers are added and mixed together to obtain acidified milk beverage containing more than 1.0% protein, and after being sterilized, its shelf life can reach to 3-6 months. Since such products are not fermented by lactic acid bacteria, the nutrition value is not high.
- It is desirable for the manufactory of acidified milk beverage that viable lactobacillus can be added into direct-acidified milk beverage and kept viable for long time without negative influence to its taste. However, up to now, no relevant technology has been reported. Usually when lactobacillus is added into milk, they will metabolize lactose to produce lactic acid, thereby make the mouthfeel of product unacceptable to consumers. Meanwhile, the activity of lactobacillus is decreased gradually; by the end viable cell count can not be measured. And ambient temperature environment will speed up the process greatly.
- Some documents have reported processes for increasing the viable cell count of lactobacillus. These processes include: adding antioxidant (such as VC), adding prebiotics(such as oligosaccharides), encapsulating lactobacillus into microcapsule, non-adding Lactobacillus bulgaricus and decreasing oxidation-reduction potential (such as adding cysteine) etc . . . (NP. Shah, Probiotic bacteria: Selective enumeration and survival in dairy foods, J. Dairy Sci., 83:894-907, 2000; A. Lourensand B. C. Vijoen Int. Dairy J., 11: 1-17, 2001). However, the effect of these processes is very limited.
- Lactobacillus rhamnosus (available from American Type Culture Collection, bacterial strain number: ATCC 53103 ) is a probiotic strain isolated from healthy human body (U.S. Pat. No. 4,839,281; U.S. Pat. No. 5,032,399), and it can get rid of endotoxin from blood plasma (U.S. Pat. No. 5,413,785). The distinctive character of this bacterium is that it does not metabolize lactose and is resistant to acid and oxygen. Since this bacterium has the function of prevention and treatment of stomach upset (such as diarrhea) and improvement of immunity, it is used in healthy and functional products (such as yoghourt). The details of the biological characteristics and probiotic function of this bacterium please refer to above-mentioned patents and review article M. Saxelin, Lactobacillus GG A human probiotic strain with thorough clinical documentation, Food Rev. Int., 13 :293-313, 1997.
- One aspect of the invention is to provide a process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature.
- The process according to an embodiment of the invention includes: according to the characters of Lactobacillus rhamnosus ATCC 53103 that it can not metabolize lactose to produce lactic acid and can survive for a long time, adding this bacterium into direct-acidified milk beverage under aseptic conditions, meanwhile adding 0.01-5% wt of growth promoting factors, thereby obtaining direct-acidified milk beverage keeping high viable cell count at ambient temperature during storage.
- The term “ambient temperature” herein refers to a temperature which can be reached indoor under normal conditions, such as 0-40° C., preferably 10-30° C.
- In the process according to an embodiment of the invention, milk is directly acidified to pH value 4.0-4.5 without fermentation, so as to obtain acidified milk beverage. Then sterilize and add concentrated culture, concentrated frozen culture or freeze dried culture of Lactobacillus rhamnosus ATCC 53103 together with 0.01-3% wt of growth promoting factors under aseptic condition.
- Wherein, said milk beverage is made from fresh milk or reconstituted milk (including but not limited to fresh milk or reconstituted milk of cow milk or goat milk). The protein concentration of the milk beverage is 0.1-4%. Preferably, the protein concentration of the milk beverage is 0.7-2.5%.
- In the process according to an embodiment of the invention, the acidulants for adjusting pH value can be any acidulants which are known by people skilled in the art, such as one or more of citric acid, lactic acid and malic acid.
- The pH value of finished product of direct-acidified milk beverage is 3.5-4.8, preferably 3.7-4.4.
- In the process according to an embodiment of the invention, the addition amount of Lactobacillus rhamnosus ATCC 53103 is not limited theoretically. According to the principle of economy and effectiveness, the addition amount of Lactobacillus rhamnosus ATCC 53103 is 103-108cfu/ml milk beverage, preferably 104-107 cfu/ml milk beverage.
- In the process according to an embodiment of the invention, above-mentioned growth promoting factors can be any growth promoting ingredients known by people skilled in the art that can be utilized by Lactobacillus rhamnosus except lactose. Preferably, said growth promoting factors can be selected from one or more of glucose, fructose, galactose, arabinose, ribose, mannose, rhamnose, fucose, tagatose, sucrose, maltose, cellobiose, trehalose, melizitose, gentiobiose, galactitol, mannitol, sorbitol, inositol, gluconic acid, salicin, aescine, arbutin, amygdalin and acetylglucosamine, and the addition amount is 0.01-5% wt. It can be added together with milk base before sterilization or with Lactobacillus rhamnosus ATCC 53103 after sterilization under aseptic condition.
- More preferably, the growth promoting factors are selected from one or more of glucose, fructose, galactose and sucrose, the addition amount is 0.05-3% wt.
- Sweeters, flavorings, stabilizers and preservatives can also be added into the above-mentioned direct-acidfied milk beverage.
- Wherein, sweeters can be selected from one or more of aspartame, Acesulfame-K (Ace-K), Sodium cyclamate, stevia sugar (stevioside) and Trichlorosucrose. And the addition amount can be 0.001-5 g/L, preferably 0.1-1 g/L.
- Flavourings can be selected as seasoners, and the addition amount can be 0.001-5 g/L, preferably 0.1-1 g/L.
- Stabilizers are selected from one or more of pectin, gelatin, modified starch, glyceryl monostearate, sucrose esters and sodium carboxymethyl Cellulose, and the addition amount can be 0.001-12 g/L, preferably 0.1-10 g/L.
- Preservatives are selected from one or more of natamycin and potassium sorbate. And the addition amount is 0.001-3 g/L, preferably 0.005-0.5 g/L.
- The direct-acidified milk beverage prepared by the process according to an embodiment of the invention can be stored for 1-6 months under room temperature (10-30° C.) and keep viable cell count at least 105 cfu/ml milk beverage. The indexes of storage period and viable cell count are much higher than fermented milk beverage prepared by conventional process. Thereby the defects that directed-acidified milk beverage has no viable Lactobacillus and has low nutritional value are overcome.
- The following examples are used to illustrate the invention, but not to limit the scope of the invention.
- Add 3.5% whole milk powder into fresh milk containing 11.5% milk solid; thereby obtain whole milk with 15% milk solid. Use 700 ml of water at 70° C. to resolve acidic milk beverage stabilizer SY-601 (provide by BEIING FUMENGTE BIOTECHNOLOGY COMPANY LTD.) 6 g and Ace-K ( available from ZHANGJIAGUANG HAOBO CHEMISTRY COMPANY) 5 g, stir for 20 minutes and cool down to below 25° C. After hydration for 30 minutes, add 200 ml above mentioned reconstituted whole milk into 700 ml stabilizer solution and stir for 5 minutes. Adjust the pH value of the mixture to 4.5 with 10% citric acid, adjust the volume to 1000 ml with water, continue to stir for 5 minutes. Preheat to 70° C., then homogenize with pressure 20 MPa, then sterilize at 115° C. for 15 minutes. The above procedure is the conventional method to prepare direct acidified milk beverage which is known to people skilled in this field.
- Cool it down to below 37° C., inoculate this acidified milk beverage with Lactobacillus rhamnosus ATCC 53103 ( concentrated culture) with quantity of 1.5×106 cfu/ml and 0.02% glucose aseptically. Keep the milk beverage at 37° C. for 15 days then 28° C. for 45 days, measure its pH value, acidity and viable cell count. The results are listed in table 1.
-
TABLE 1 Viability of lactobacillus and the pH value & acidity variation of the acidified milk beverage during storage Viable cell Storage storage time Titratable count (×106/ml temperature (day) pH value acidity milk beverage) 37° C. 0 4.50 35 1.5 1 4.44 33 22 3 4.47 35 16.7 6 4.50 35 14.2 9 4.53 31 3 12 4.53 31 3.6 15 4.54 30 3.6 28° C. 18 4.57 28 2.5 24 4.52 32 1.2 27 4.57 28 1.6 30 4.56 31 0.9 37 4.56 31 1.1 60 4.59 29 0.68 - Prepare reconstituted whole milk with 10% whole milk powder and make a mixture with 1.0% milk protein by the same process as in Example 1, adjust the pH value of the mixture to 4.2 with 10% lactic acid. Adding 0.1% glucose, 0.4% sucrose inside the mixture, homogenize and sterilize, then cool it down to below 37° C., add Lactobacillus rhamnosus ATCC 53103 (concentrated frozen culture) with quantity of 1.5×105 cfu/ml into above-mentioned acidified milk beverage, store it at 12-25° C. Measure the pH value and viable cell count in different storage period. The results are listed in table 2.
-
TABLE 2 Viability of lactobacillus and pH value variation of the acidified milk beverage during storage Viable cell count storage (106 cfu/ml time (month) pH value milk beverage) 0 4.2 2 1 3.8 98 2 3.82 34 3 3.80 7.6 4 3.85 2.1 5 3.85 0.9 6 3.83 0.25 - With the same process in Example 1, make reconstituted whole milk with 4.5% whole milk powder, and acidify it. Adjust the pH value of the mixture to 4.0 with 10% lactic acid. Homogenize and sterilize, then cool it down to below 37° C., add Lactobacillus rhamnosus ATCC 53103 (freeze dried culture powder) with quantity of 2×106 cfu/ml and 0.15% galactose into above-mentioned milk beverage aseptically, store it at 12-25° C. Measure its acidity and viable cell count during storage. The results are listed in table 3
-
TABLE 3 Viability of lactobacillus and pH value variation of the acidified milk beverage during storage Viable cell count storage (106 cfu/ml time (month) pH value milk beverage) 0 4.2 0.15 1 4.1 210 2 4.09 180 3 4.11 110 4 4.08 82 5 4.07 32 6 4.08 8.5 - With the same process in Example 1, make reconstituted whole milk with 7% whole milk powder, and acidify it. Adjust the pH value of the mixture to 4.4 with 10% malic acid. Homogenize and sterilize, then cool it down to below 37° C., add Lactobacillus rhamnosus ATCC 53103 ( concentrated frozen culture) with quantity of 2×107 cfu/ml and 0.02% fructose into above-mentioned milk beverage aseptically, store it at 12-25° C. Measure the pH value and viable cell count during storage. The results are listed in table 4.
-
TABLE 4 Viability of lactobacillus and pH value variation of the acidified milk beverage during storage Viable cell count storage (106 cfu/ml time (month) pH value milk beverage) 0 4.40 20 1 4.30 245 2 4.31 178 3 4.30 105 4 4.28 92 5 4.35 65 6 4.29 48
Claims (20)
1. A process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature, wherein milk beverage is not through fermentation, directly by adjusting pH value to 4.0-4.5 to obtain acidified milk beverage, then sterilizing, adding concentrated culture, concentrated frozen culture or freeze dried culture of Lactobacillus rhamnosus ATCC 53103 together with 0.01-3% wt of growth promoting factors under aseptic condition.
2. The process according to claim 1 , wherein said milk beverage is made from fresh milk or reconstituted milk, the protein concentration of the milk beverage is 0.1-4%;
3. The process according to claim 2 , wherein the protein concentration of the milk beverage is 0.7-2.5%.
4. The process according to claim 1 , wherein the acidulants for adjusting pH value are selected from one or more of citric acid, lactic acid and malic acid.
5. The process according to claim 1 , wherein the pH value of the finished product of acidified milk beverage is 3.5-4.8.
6. The process according to claim 5 , wherein the pH value of the finished product of acidified milk beverage is 3.7-4.4.
7. The process according to claim 1 , wherein said addition amount of Lactobacillus rhamnosus ATCC 53103 is 103-108 cfu/ml milk beverage.
8. The process according to claim 7 , wherein said addition amount of Lactobacillus rhamnosus ATCC 53103 is 104-107 cfu/ml milk beverage.
9. The process according to claim 1 , wherein said growth promoting factors are selected from one or more of glucose, fructose, galactose, arabinose, ribose, mannose, rhamnose, fucose, tagatose, sucrose, maltose, cellobiose, trehalose, melizitose, gentiobiose, galactitol, mannitol, sorbitol, inositol, gluconic acid, salicin, aescine, arbutin, amygdalin and acetylglucosamine, the addition amount is 0.01-5%, and it can be added together with milk base before sterilization or with Lactobacillus rhamnosus ATCC 53103 under aseptic condition.
10. The process according to claim 9 , wherein said growth promoting factor is selected from one or more of glucose, fructose, galactose, sucrose, and the addition amount is 0.05-3%.
11. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 1 .
12. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 2 .
13. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 3 .
14. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 4 .
15. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 5 .
16. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 6 .
17. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 7 .
18. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 8 .
19. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 9 .
20. A direct-acidified milk beverage keeping high viable cell count at ambient temperature prepared by the process according to claim 10 .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710064896.X | 2007-03-28 | ||
| CN200710064896 | 2007-03-28 | ||
| PCT/CN2007/002035 WO2008116355A1 (en) | 2007-03-28 | 2007-06-29 | A method for preparing ambient-stable direct-acidified milk beverage with high counts of viable lactic acid bacteria |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2007/002035 Continuation-In-Part WO2008116355A1 (en) | 2007-03-28 | 2007-06-29 | A method for preparing ambient-stable direct-acidified milk beverage with high counts of viable lactic acid bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20100015285A1 true US20100015285A1 (en) | 2010-01-21 |
Family
ID=39788021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/564,744 Abandoned US20100015285A1 (en) | 2007-03-28 | 2009-09-22 | Process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature |
| US12/564,762 Active 2029-10-20 US10072310B2 (en) | 2007-03-28 | 2009-09-22 | Process of preparing fermented milk beverage keeping high viable cell count at ambient temperature |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/564,762 Active 2029-10-20 US10072310B2 (en) | 2007-03-28 | 2009-09-22 | Process of preparing fermented milk beverage keeping high viable cell count at ambient temperature |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20100015285A1 (en) |
| CN (3) | CN101273736B (en) |
| WO (2) | WO2008116355A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130259977A1 (en) * | 2010-11-18 | 2013-10-03 | Meiji Co., Ltd. | Fermented milk with reduced sourness and method for producing same |
| US20160227828A1 (en) * | 2015-02-05 | 2016-08-11 | Abbott Laboratories | Substantially clear nutritional liquids having improved sensory characteristics |
| WO2021048350A1 (en) | 2019-09-12 | 2021-03-18 | Chr. Hansen A/S | Lactic acid bacteria for a heat-treated food product for storage at ambient temperature |
| US11606965B2 (en) | 2016-05-11 | 2023-03-21 | Chr. Hansen A/S | Lactic acid bacteria for a heat-treated food product for storage at ambient temperature |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE533537C2 (en) * | 2009-06-18 | 2010-10-19 | Tetra Laval Holdings & Finance | Method for making a yogurt-based product |
| CN101700061B (en) * | 2009-10-28 | 2012-06-27 | 山东康智多生物科技有限公司 | High-activity fermented milk beverage and preparation method thereof |
| CN101708018B (en) * | 2009-12-14 | 2013-03-13 | 杭州味全食品有限公司 | Lactobacillus-casei probiotics beverage and preparation method thereof |
| CN102618456B (en) * | 2012-02-28 | 2013-08-21 | 江南大学 | Lactobacillus rhamnosus capable of relieving chronic alcohol liver injury and application thereof |
| EP2825207B1 (en) * | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| KR101381794B1 (en) * | 2012-04-10 | 2014-04-07 | 씨제이제일제당 (주) | Synbiotic food composition containing tagatose and probiotic lactic acid bacteria |
| CN103564043A (en) * | 2012-07-24 | 2014-02-12 | 内蒙古蒙牛乳业(集团)股份有限公司 | Fermented milk containing lactobacillus rhamnosus |
| CN104957256A (en) * | 2015-07-01 | 2015-10-07 | 新疆香格尔食品有限责任公司 | Fermentation type double-protein milk beverage and preparation method thereof |
| EP3344749A1 (en) * | 2015-08-31 | 2018-07-11 | Chr. Hansen A/S | Lactobacillus fermentum bacteria with antifungal activity |
| CN105230784A (en) * | 2015-10-29 | 2016-01-13 | 光明乳业股份有限公司 | Viable bacteria type room-temperature fermented milk beverage and preparation method of viable bacteria type room-temperature fermented milk beverage |
| CN105707648A (en) * | 2016-01-29 | 2016-06-29 | 江苏微康生物科技有限公司 | Anti-fungus biological protection agent and application thereof |
| CN106234891A (en) * | 2016-02-05 | 2016-12-21 | 上海交大昂立股份有限公司 | High-activity probiotics fermenting plant beverage that a kind of room temperature preserves and preparation method thereof |
| CN105961588A (en) * | 2016-05-03 | 2016-09-28 | 新希望乳业控股有限公司 | Probiotic lactobacillus rhamnosus fermented milk and preparation method thereof |
| CN105961589A (en) * | 2016-05-17 | 2016-09-28 | 安徽新希望白帝乳业有限公司 | Preparation method of brown set-style yogurt capable of resisting post-acidification |
| KR20180066828A (en) * | 2016-12-09 | 2018-06-19 | 씨제이제일제당 (주) | Fermented milk comprising saccharides comprising high content of allulose |
| CN109497136A (en) * | 2017-09-14 | 2019-03-22 | 内蒙古蒙牛乳业(集团)股份有限公司 | A kind of post-fermentation room temperature viable bacteria sour milk and preparation method thereof |
| CN110279117A (en) * | 2018-03-19 | 2019-09-27 | 医迈霖科技公司 | A kind of probiotics frozen dried food |
| CN108813592A (en) * | 2018-06-13 | 2018-11-16 | 北京颐和村生物科技有限公司 | A kind of preparation method for the vegetarian product that ferments |
| CN109548875A (en) * | 2018-10-30 | 2019-04-02 | 徐州汇尔康食品有限公司 | A kind of rich selenium germanium Lactic acid bacteria drink article formulations |
| CN111227035A (en) * | 2018-11-28 | 2020-06-05 | 内蒙古伊利实业集团股份有限公司 | Fermented milk containing probiotic composition and preparation method thereof |
| CN111248269A (en) * | 2018-11-30 | 2020-06-09 | 内蒙古伊利实业集团股份有限公司 | Lactobacillus rhamnosus-containing probiotic fermented milk and preparation method thereof |
| CN109527089B (en) * | 2018-12-19 | 2022-01-18 | 扬州市扬大康源乳业有限公司 | Probiotic fresh milk and preparation method thereof |
| CN109619180B (en) * | 2018-12-30 | 2022-09-23 | 光明乳业股份有限公司 | Viable bacteria type normal-temperature fermented milk and preparation method thereof |
| CN112167339A (en) * | 2020-10-16 | 2021-01-05 | 光明乳业股份有限公司 | Lactobacillus rhamnosus fermented milk and preparation method thereof |
| CN112715655B (en) * | 2020-12-25 | 2022-11-04 | 光明乳业股份有限公司 | Lactobacillus plantarum fermented milk powder and preparation method thereof |
| CN113121013B (en) * | 2021-04-16 | 2023-06-27 | 无锡映川环境技术有限公司 | Autotrophic denitrification filter material with active bacterial coating and preparation method thereof |
| CN113632840A (en) * | 2021-08-12 | 2021-11-12 | 河北弗蒙特生物科技有限公司 | Probiotic milk or milk-containing beverage with high viable count and preparation method thereof |
| CA3232198A1 (en) * | 2021-10-04 | 2023-04-13 | Hui Han | Method for producing fermented milk products for ambient storage |
| CN114052081A (en) * | 2021-11-22 | 2022-02-18 | 光明乳业股份有限公司 | Normal-temperature live bacterium yoghourt and preparation method thereof |
| CN116762858B (en) * | 2022-03-07 | 2025-09-19 | 内蒙古伊利实业集团股份有限公司 | Preparation method of normal-temperature viable bacteria fermented milk |
| CN115152842A (en) * | 2022-07-13 | 2022-10-11 | 光明乳业股份有限公司 | Lactobacillus fermentum normal-temperature milk beverage and preparation method thereof |
| CN115281247A (en) * | 2022-07-13 | 2022-11-04 | 光明乳业股份有限公司 | Lactobacillus fermentum normal-temperature yogurt and preparation method thereof |
| CN115136986A (en) * | 2022-07-13 | 2022-10-04 | 光明乳业股份有限公司 | Lactobacillus fermentum solid beverage and preparation method thereof |
| CN115997822B (en) * | 2022-12-21 | 2024-02-23 | 光明乳业股份有限公司 | Lactobacillus reuteri normal-temperature yoghourt and preparation method thereof |
| CN115943995B (en) * | 2022-12-21 | 2024-03-01 | 光明乳业股份有限公司 | Lactobacillus reuteri normal-temperature milk beverage and preparation method thereof |
| AU2024256668A1 (en) | 2023-04-20 | 2025-10-23 | Chr. Hansen A/S | Storage stable lacticaseibacillus rhamnosus |
| CN116508922A (en) * | 2023-05-21 | 2023-08-01 | 江西蒙天乳业有限公司 | Preparation method of normal-temperature lactobacillus |
| CN119464163B (en) * | 2025-01-15 | 2025-07-01 | 山东捷晶生物科技有限公司 | Lactobacillus rhamnosus Lr-Ca011, metagen and calcium product for promoting calcium absorption and nanoemulsion homogenization preparation method thereof |
Citations (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4169854A (en) * | 1977-05-12 | 1979-10-02 | Merck & Co., Inc. | Direct acidified yogurt |
| US4839281A (en) * | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| US5413785A (en) * | 1993-01-27 | 1995-05-09 | New England Deaconess Hospital Corp. | Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo |
| US5709857A (en) * | 1994-05-26 | 1998-01-20 | Dibra S.P.A. | Lactobacillus strains of human origin, their compositons and uses thereof |
| US6007808A (en) * | 1995-06-23 | 1999-12-28 | Dibra S.P.A. | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders |
| US6156320A (en) * | 1993-02-05 | 2000-12-05 | Harry Parsekian | Fermented milk nutraceuticals |
| WO2001088510A2 (en) * | 2000-05-18 | 2001-11-22 | Argose, Inc. | Pre-and post-processing of spectral data for calibration using multivariate analysis techniques |
| US20020028269A1 (en) * | 2000-06-13 | 2002-03-07 | Lipton, Division Of Conopco, Inc. | Lactobacillus containing product |
| US6358521B1 (en) * | 1993-02-05 | 2002-03-19 | Harry Parsekian | Fermented milk nutraceuticals |
| US6506380B1 (en) * | 1995-06-14 | 2003-01-14 | Valio Oy | Methods of preventing or treating allergies |
| US6596530B1 (en) * | 1999-06-24 | 2003-07-22 | Meiji Dairies Corporation | Strain of Lactobacillus gasseri |
| US20030147857A1 (en) * | 2002-02-05 | 2003-08-07 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
| US20040067573A1 (en) * | 2002-10-07 | 2004-04-08 | Eamonn Connolly | Selection and use of lactic acid bacteria for reducing inflammmation caused by helicobacter |
| US20040115773A1 (en) * | 2001-01-30 | 2004-06-17 | Fabrizio Arigoni | Serpin in bifidobacteria |
| US6835376B1 (en) * | 1999-03-11 | 2004-12-28 | Nestec S.A. | Lactobacillus paracasei strain for preventing diarrhea caused by pathogenic bacteria |
| US20050002874A1 (en) * | 2003-01-29 | 2005-01-06 | Bo Mollstam | Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries |
| US6872565B2 (en) * | 2003-01-29 | 2005-03-29 | Biogaia Ab | Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries |
| US6926891B1 (en) * | 1999-08-05 | 2005-08-09 | Nestec S.A. | Treatment of diarrhea with strains of Bifidobacterium longum |
| US6942849B2 (en) * | 1998-08-12 | 2005-09-13 | Nestec S.A. | Incorporation of exogenous lactic bacteria into the oral microflora |
| US20060013806A1 (en) * | 2000-06-20 | 2006-01-19 | Erika Isolauri | Probiotics in primary prevention of atopic diseases |
| US7029669B1 (en) * | 1999-03-11 | 2006-04-18 | Nestec S. A. | Lactic acid bacteria strains capable of preventing diarrhoea |
| US20060165661A1 (en) * | 2003-06-13 | 2006-07-27 | N>V> Nutricia | Pediocin-producing pediococci |
| US20070110849A1 (en) * | 2003-06-23 | 2007-05-17 | Marie-Christine Secretin | Infant or follow-on formula |
| US20070123460A1 (en) * | 2004-04-20 | 2007-05-31 | The University Of Chicago | Probiotic compounds from Lactobacillus GG and uses therefor |
| US20070269515A1 (en) * | 2003-12-24 | 2007-11-22 | Henriksen Kristian L | Probiotic Tablet Formulations |
| US20080095752A1 (en) * | 2006-10-20 | 2008-04-24 | Win-Chin Chiang | Method for extending the shelf-life of powdered nutritional formulations which contain viable probiotics |
| US20090274661A1 (en) * | 2006-02-15 | 2009-11-05 | Nestec S.A. | Use of bifidobacterium longum for the prevention and treatment of inflammation |
| US20110020304A1 (en) * | 2008-03-14 | 2011-01-27 | Nestec S.A. | Synbiotic mixture |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL41570A (en) * | 1973-02-19 | 1976-02-29 | For Ind Res Ltd Centre | A method for manufacture of non-dairy yoghurt product |
| US4748025A (en) * | 1986-02-24 | 1988-05-31 | Rutgers, The State University Of New Jersey | Novel cultured buttermilk compositions and method of preparation |
| CN1097095A (en) * | 1993-07-07 | 1995-01-11 | 汪群 | Fresh-keeping flavour sour milk product |
| CN1129522A (en) * | 1995-02-21 | 1996-08-28 | 魏立华 | Activated lactic acid bacteria milk |
| CN1160451C (en) * | 2000-10-16 | 2004-08-04 | 鼎健生物科技食品股份有限公司 | Rhamnose lactic acid bacteria strain and its use |
| FI109602B (en) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probiotkombination |
| CN1357269A (en) * | 2001-12-21 | 2002-07-10 | 李道光 | Active lactic acid bacteria beverage and its prepn |
| FI113057B (en) * | 2002-11-04 | 2004-02-27 | Valio Oy | Use of Lactobacillus rhamnosus LGG deposited under ATCC 53103, Lactobacillus rhamnosus LC705, DSM 7061, and Propionibacterium freudenreichii PJS, DSM 7067 for preparing a product for inhibiting yeast |
| JP2007028920A (en) * | 2005-07-22 | 2007-02-08 | Japan Research & Development Association For New Functional Foods | Fermented milk and method for producing the same |
| CN100484405C (en) * | 2006-07-21 | 2009-05-06 | 华南理工大学 | Method for preparing active lactic acid bacteria beverage |
-
2007
- 2007-06-18 CN CN2007101112377A patent/CN101273736B/en active Active
- 2007-06-18 CN CN2007101112381A patent/CN101273738B/en active Active
- 2007-06-18 CN CN2007101112362A patent/CN101273737B/en active Active
- 2007-06-29 WO PCT/CN2007/002035 patent/WO2008116355A1/en not_active Ceased
- 2007-06-29 WO PCT/CN2007/002037 patent/WO2008116356A1/en not_active Ceased
-
2009
- 2009-09-22 US US12/564,744 patent/US20100015285A1/en not_active Abandoned
- 2009-09-22 US US12/564,762 patent/US10072310B2/en active Active
Patent Citations (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4169854A (en) * | 1977-05-12 | 1979-10-02 | Merck & Co., Inc. | Direct acidified yogurt |
| US4839281A (en) * | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| US5032399A (en) * | 1985-04-17 | 1991-07-16 | Sherwood L. Gorbach | L. acidophilus strains |
| US5413785A (en) * | 1993-01-27 | 1995-05-09 | New England Deaconess Hospital Corp. | Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo |
| US6156320A (en) * | 1993-02-05 | 2000-12-05 | Harry Parsekian | Fermented milk nutraceuticals |
| US6358521B1 (en) * | 1993-02-05 | 2002-03-19 | Harry Parsekian | Fermented milk nutraceuticals |
| US5709857A (en) * | 1994-05-26 | 1998-01-20 | Dibra S.P.A. | Lactobacillus strains of human origin, their compositons and uses thereof |
| US6506380B1 (en) * | 1995-06-14 | 2003-01-14 | Valio Oy | Methods of preventing or treating allergies |
| US20030113340A1 (en) * | 1995-06-14 | 2003-06-19 | Valio Oy | Methods of promoting tolerogenic immune responses and compositions therefor |
| US6007808A (en) * | 1995-06-23 | 1999-12-28 | Dibra S.P.A. | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders |
| US6942849B2 (en) * | 1998-08-12 | 2005-09-13 | Nestec S.A. | Incorporation of exogenous lactic bacteria into the oral microflora |
| US6835376B1 (en) * | 1999-03-11 | 2004-12-28 | Nestec S.A. | Lactobacillus paracasei strain for preventing diarrhea caused by pathogenic bacteria |
| US7029669B1 (en) * | 1999-03-11 | 2006-04-18 | Nestec S. A. | Lactic acid bacteria strains capable of preventing diarrhoea |
| US6596530B1 (en) * | 1999-06-24 | 2003-07-22 | Meiji Dairies Corporation | Strain of Lactobacillus gasseri |
| US20030161820A1 (en) * | 1999-06-24 | 2003-08-28 | Meiji Milk Products Company, Limited | Food or drink product with a disinfection property of helicobacter pylori |
| US6926891B1 (en) * | 1999-08-05 | 2005-08-09 | Nestec S.A. | Treatment of diarrhea with strains of Bifidobacterium longum |
| WO2001088510A2 (en) * | 2000-05-18 | 2001-11-22 | Argose, Inc. | Pre-and post-processing of spectral data for calibration using multivariate analysis techniques |
| US20020028269A1 (en) * | 2000-06-13 | 2002-03-07 | Lipton, Division Of Conopco, Inc. | Lactobacillus containing product |
| US20060013806A1 (en) * | 2000-06-20 | 2006-01-19 | Erika Isolauri | Probiotics in primary prevention of atopic diseases |
| US7112322B2 (en) * | 2000-06-20 | 2006-09-26 | Erika Isolauri | Probiotics in primary prevention of atopic diseases |
| US20040115773A1 (en) * | 2001-01-30 | 2004-06-17 | Fabrizio Arigoni | Serpin in bifidobacteria |
| US7101565B2 (en) * | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
| US20030147857A1 (en) * | 2002-02-05 | 2003-08-07 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
| US20040067573A1 (en) * | 2002-10-07 | 2004-04-08 | Eamonn Connolly | Selection and use of lactic acid bacteria for reducing inflammmation caused by helicobacter |
| US20050002874A1 (en) * | 2003-01-29 | 2005-01-06 | Bo Mollstam | Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries |
| US20050158254A1 (en) * | 2003-01-29 | 2005-07-21 | Bo Mollstam | Use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries |
| US6872565B2 (en) * | 2003-01-29 | 2005-03-29 | Biogaia Ab | Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries |
| US20060165661A1 (en) * | 2003-06-13 | 2006-07-27 | N>V> Nutricia | Pediocin-producing pediococci |
| US20070110849A1 (en) * | 2003-06-23 | 2007-05-17 | Marie-Christine Secretin | Infant or follow-on formula |
| US20070269515A1 (en) * | 2003-12-24 | 2007-11-22 | Henriksen Kristian L | Probiotic Tablet Formulations |
| US20070123460A1 (en) * | 2004-04-20 | 2007-05-31 | The University Of Chicago | Probiotic compounds from Lactobacillus GG and uses therefor |
| US20090274661A1 (en) * | 2006-02-15 | 2009-11-05 | Nestec S.A. | Use of bifidobacterium longum for the prevention and treatment of inflammation |
| US20080095752A1 (en) * | 2006-10-20 | 2008-04-24 | Win-Chin Chiang | Method for extending the shelf-life of powdered nutritional formulations which contain viable probiotics |
| US20110020304A1 (en) * | 2008-03-14 | 2011-01-27 | Nestec S.A. | Synbiotic mixture |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130259977A1 (en) * | 2010-11-18 | 2013-10-03 | Meiji Co., Ltd. | Fermented milk with reduced sourness and method for producing same |
| US20160227828A1 (en) * | 2015-02-05 | 2016-08-11 | Abbott Laboratories | Substantially clear nutritional liquids having improved sensory characteristics |
| US11606965B2 (en) | 2016-05-11 | 2023-03-21 | Chr. Hansen A/S | Lactic acid bacteria for a heat-treated food product for storage at ambient temperature |
| WO2021048350A1 (en) | 2019-09-12 | 2021-03-18 | Chr. Hansen A/S | Lactic acid bacteria for a heat-treated food product for storage at ambient temperature |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101273737A (en) | 2008-10-01 |
| CN101273738A (en) | 2008-10-01 |
| US10072310B2 (en) | 2018-09-11 |
| WO2008116355A1 (en) | 2008-10-02 |
| US20100009034A1 (en) | 2010-01-14 |
| WO2008116356A1 (en) | 2008-10-02 |
| CN101273736B (en) | 2012-08-08 |
| CN101273737B (en) | 2011-08-24 |
| CN101273738B (en) | 2011-06-01 |
| CN101273736A (en) | 2008-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100015285A1 (en) | Process of preparing direct-acidified milk beverage keeping high viable cell count at ambient temperature | |
| CA2753083C (en) | Symbiotic maple product compositions and methods | |
| KR101859992B1 (en) | Cereals fermented by lactic acid bacteria and method for manufacturing the same | |
| CN107873841B (en) | Lactic acid bacteria beverage and production process thereof | |
| CN103999935A (en) | Post-acidification resistant fermented yogurt and preparation method thereof | |
| CN106578064B (en) | Donkey-hide gelatin and lactic acid bacteria beverage and preparation method thereof | |
| TWI661775B (en) | Fermented milk comprisingsaccharides comprising allulose, method of improving storability of fermented milk, and growth inhibitor for microorganisms | |
| CN105982108B (en) | Carrot juice beverage and preparation method thereof | |
| US7326558B2 (en) | Process for treating spirulina | |
| CN101144064B (en) | Lactobacillus brevis with anti-mutagenesis active and capable of producing exopolysaccharide and use thereof | |
| JP5268916B2 (en) | Acid lactic acid bacteria beverage, method for producing acid lactic acid bacteria beverage, and method for improving survival of bifidobacteria | |
| CN110710627A (en) | Functional probiotic solid beverage and preparation method thereof | |
| KR20230001022A (en) | A process for the preparation of sikhye containing lactobacillus and the sikhye containing lactobacillus prepared therefrom | |
| RU2273662C2 (en) | Consortium of microorganisms with probiotic effect | |
| ES2250326T3 (en) | CARBON ADDITIVE FOR FOOD FERMENTATIONS AND FOOD COMPOUNDS THAT CONTAIN IT. | |
| CN104651262B (en) | A kind of lactobacillus plantarum lyophilized preparation and its preparation method and application | |
| CN109315693A (en) | A kind of fermented sea buckthorn pudding and preparation method thereof | |
| JP3925502B2 (en) | Novel lactic acid bacteria, fermented soymilk obtained using the same, and method for producing the same | |
| CN115152842A (en) | Lactobacillus fermentum normal-temperature milk beverage and preparation method thereof | |
| KR20100010556A (en) | A method for preparing a herbal fermented functional liquid having a excellent sense effect and economical efficiency | |
| KR102817171B1 (en) | Lactic acid bacteria fermented beverage using ultra-fine red pepper powder and method for manufacturing the same | |
| CN110574847A (en) | Active fruit juice and preparation method thereof | |
| Paliy et al. | Influence of various prebiotic components on the main growth indicators of probiotic bacteria | |
| KR20020033566A (en) | Production process for foodstuff fermenting agents | |
| KR101706842B1 (en) | Bop-Sikhae and Manufacturing Method Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: BEIJING YIHECUN TECH. CO., LTD.,CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LING, HAIBO;REEL/FRAME:023277/0335 Effective date: 20090912 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |